Roger Owen summarizes the status of emerging therapeutic agents for the treatment of patients with Waldenström’s macroglobulinemia, highlights those that appear most promising, even after failing BTK inhibitors, talks about how to guide treatment decisions, the influence of the mutation profile and expectations of BTK inhibitors in patients with relapsed and refractory marginal zone lymphoma.